• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Boston Scientific touts Taxus Express2 trial results

Boston Scientific touts Taxus Express2 trial results

May 7, 2009 By MassDevice staff

Boston Scientific Corp. is touting a clinical trial comparing one of its drug-eluting stents with a bare-metal stent, published today in the New England Journal of Medicine.

The Natick devices goliath, which helped fund the study along with the Cardiovascular Research Foundation and The Medicines Co., said the study, called the Horizons AMI trial, showed patients fared better one year after implantation with its Taxus Express2 paclitaxel-eluting stent than patients with its Express bare-metal stent.

The trial, of 3,006 patients with acute myocardial infarctions, involved implanting about two-thirds with the drug-eluting stent and the remaining 749 patients with the bare metal stent.

A year later, 4.5 percent of patients who received the DE stents required ischemia-driven target-lesion revascularization, compared with 7.5 percent of patients implanted with the bare stents. Target-vessel revascularization rates were also lower for the DES patients (5.8 percent vs. 8.7 percent).

In plain English, that means fewer patients with the drug-coated devices required further procedures to re-open their narrowed blood vessels.

The two devices had the same death rates after a year (3.5 percent) and similar rates of blood clots (known as stent thrombosis), at 3.2 percent and 3.4 percent, respectively.

After 13 months, the rate of binary restenosis (re-narrowing of the artery) was significantly lower for patients with the paclitaxel-eluting stents (10 percent vs. 22.9 percent for patients with the bare-metal devices).

Lead investigator Gregg Stone, a medicine professor and director of research and education at Columbia University Medical Center/New York-Presbyterian Hospital’s Center for Interventional Vascular Therapy, said the the patients in the trial will be tracked for five years to whether the results hold up.

News of the study’s results sent BSC’s stock up about 3.5 percent as of 2 p.m. today, to $8.80 after opening at $8.50.

The trial, the latest to investigate the effectiveness of drug-eluting stents, follows a comparison of the Taxus device with its Xience V competitor from Abbott Laboratories. The Taxus didn’t fare so well in that three-year study, which indicated that rates of major cardiovascular events for the Xience stent topped out at 6.4 percent during the second and third years; the Taxus device hit 10.5 percent for the second year and 14.9 percent for the third year.

The Abbott stent also showed a lower mortality rate than the Taxus, although neither caused a large number of deaths or serious complications.

One wrinkle is that Boston Scientific also markets Xience under the private-label Promus brand, though it pays royalties from those sales back to Abbott.

Filed Under: Business/Financial News, Drug-Eluting Stents

More recent news

  • Preceptis Medical has a new CEO as it advances ear tube tech
  • FDA clears first over-the-counter cuffless blood pressure monitor
  • Mendaera wins FDA clearance for robotic needle placement
  • Johnson & Johnson seeks to have $442 million antitrust verdict tossed out
  • Former Masimo COO is joining BD to run Connected Care

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy